SequelSEC

Tectonic Therapeutic, Inc. TECX

Biological Products, (No Diagnostic Substances) · CIK 0001681087 · Fiscal year ends 1231

Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$84.04M
Fiscal year ended 2025-12-31
Free cash flow
-$60.29M
Fiscal year ended 2025-12-31

Tectonic Therapeutic, Inc. (TECX) reported net income of -$74.15M for the fiscal year ended 2025-12-31. This page shows 9 annual periods of income statement, balance sheet and cash flow figures normalized from Tectonic Therapeutic, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Tectonic Therapeutic, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$84.04M-$58.02M-$44.65M-$105.43M-$118.84M-$120.23M-$75.81M-$46.24M-$18.39M
Net income-$74.15M-$57.98M-$42.82M-$105.89M-$119.13M-$119.71M-$72.96M-$46.36M-$18.65M
Research & development$63.49M$41.36M$36.97M$72.19M$83.11M$87.24M$54.97M$35.10M$15.19M
Weighted-average diluted sharesshares 18.32Mshares 8.49Mshares 1.27Mshares 43.74MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$72.92M-$57.98MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$1.23M$0$0$0UnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-4.05$-6.83$-33.76$-2.42$-2.78UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$20.55M$16.65M$7.68M$33.25M$35.73M$32.99M$20.84M$11.15M$3.20M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Tectonic Therapeutic, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Cash & equivalents$253.80M$141.24M$28.77M$92.56M$189.57M$259.68M$187.04M$126.30M$5.96M
Total assets$261.04M$152.90M$39.40M$103.95M$203.84M$271.23M$200.51M$133.48M$7.02M
Current assets$257.36M$146.86M$30.88M$99.96M$199.14M$267.24M$195.70M$130.02M$6.31M
Total liabilities$9.71M$12.13M$43.41M$28.58M$34.36M$16.89M$14.50M$11.30M$3.66M
Current liabilities$9.67M$11.61M$40.89M$13.12M$19.39M$16.61M$14.02M$10.61M$2.62M
Total equity incl. NCI$251.33M$140.78M-$84.64M-$45.65M$169.48M$254.34M$186.01M$122.18M-$23.14M
Temporary (mezzanine) equityUnavailable$0$80.63MUnavailableUnavailableUnavailableUnavailableUnavailable$26.50M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable$15.00M$15.00MUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.09M$976.00K$409.00K$384.00K$3.49M$2.68M$3.95M$2.78M$527.00K

Cash flow

Tectonic Therapeutic, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Operating cash flow-$60.08M-$59.08M-$40.68M-$97.21M-$98.02M-$98.80M-$67.67M-$37.65M-$16.38M
Capital expenditures$208.00K$156.00K$279.00K$267.00K$2.46M$1.18M$1.58M$1.83M$383.00K
Investing cash flow-$138.00K-$156.00K-$279.00K-$267.00K-$2.46M-$1.18M-$1.58M-$1.83M-$383.00K
Financing cash flow$173.36M$171.71M$33.75M$262.00K$30.37M$172.62M$129.99M$160.29M$17.37M
Net change in cash$113.04M$112.47M-$7.20M-$97.21M-$70.12M$72.64M$60.74M$120.81M$606.00K
Stock-based compensation$10.50M$3.49M$1.12M$11.52M$18.58M$15.63M$6.80M$2.20M$177.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.38M$1.64M$1.48M$1.44M$1.40M$1.21M$850.00K$380.00K$45.00K

Derived

Tectonic Therapeutic, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Free cash flow-$60.29M-$59.24M-$40.96M-$97.48M-$100.49M-$99.98M-$69.25M-$39.48M-$16.76M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio26.63x12.65x0.76x7.62x10.27x16.09x13.96x12.26x2.40x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TECX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2022-12-31

Difference 121024000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.